The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of the immune tumor microenvironment of HER2-positive breast cancer following treatment with entinostat and immune checkpoint inhibition.
 
Evanthia T. Roussos Torres
No Relationships to Disclose
 
Dimitrios N Sidiropoulos
No Relationships to Disclose
 
Emily Davis-Marcisak
No Relationships to Disclose
 
Luciane Tsukamoto Kagohara
No Relationships to Disclose
 
Roisin M. Connolly
Research Funding - Genentech/Roche (Inst); Macrogenics (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Vered Stearns
Consulting or Advisory Role - Iridium Therapeutics
Research Funding - Abbvie; Biocept; MedImmune; Novartis; Pfizer; Puma Biotechnology
Other Relationship - Immunomedics
 
Elizabeth M. Jaffee
Consulting or Advisory Role - Adaptive Biotechnologies; CStone Pharmaceuticals; Dragonfly Therapeutics; Genocea Biosciences; Incyte
Research Funding - Aduro Biotech; Amgen; Bristol-Myers Squibb; Corvus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genocea Biosciences; MedImmune
Other Relationship - Dragonfly Therapeutics
 
Elana J. Fertig
No Relationships to Disclose